Loading
A phase 1/2 trial of Lenalidomide, Dexamethasone in multiple myeloma, run by Starton Therapeutics, Inc, now recruiting.
Safety, Efficacy, and Pharmacokinetics of Continuous Subcutaneous Lenalidomide in Multiple Myeloma (MM) is a phase 1/2 interventional study registered as NCT06087653 by Starton Therapeutics, Inc, with 24 participants planned, started 2023-10-02 and due to reach its primary completion in 2027-05-31. Interventions recorded: Lenalidomide, Lenalidomide 25 MG Oral Capsule. Conditions listed: Multiple Myeloma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Lenalidomide, Dexamethasone, PROTACs & molecular glues (targeted protein degradation), Multiple myeloma.
Shares Lenalidomide, PROTACs & molecular glues (targeted protein degradation), Multiple myeloma.
Shares Lenalidomide, Dexamethasone, PROTACs & molecular glues (targeted protein degradation), Multiple myeloma.
Shares Lenalidomide, PROTACs & molecular glues (targeted protein degradation).
Shares Lenalidomide, Dexamethasone, PROTACs & molecular glues (targeted protein degradation), Multiple myeloma.
Shares Lenalidomide, Dexamethasone, Multiple myeloma.
Shares Lenalidomide, Dexamethasone, PROTACs & molecular glues (targeted protein degradation), Multiple myeloma.
Shares Lenalidomide, PROTACs & molecular glues (targeted protein degradation).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/